Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Hohmann

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Nature Microbiology|January 8, 2026
Gut microbial ethanol metabolism contributes to auto-brewery syndrome in an observational cohortCynthia L Hsu, Shikha Shukla, Linton Freund, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 4, 2023
Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota-Based TherapeuticCharles S Berenson, Bret Lashner, Louis Y Korman, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 10, 2013
Intestinal alkaline phosphatase prevents metabolic syndrome in miceKanakaraju Kaliannan, Sulaiman R Hamarneh, Konstantinos P Economopoulos, et al.
Blood Advances|March 12, 2024
Third-party fecal microbiota transplantation for high-risk treatment-naïve acute GVHD of the lower GI tractZachariah DeFilipp, Ashish V Damania, Haesook T Kim, et al.
Blood Advances|March 30, 2018
Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversityZachariah DeFilipp, Jonathan U Peled, Shuli Li, et al.
The New England Journal of Medicine|May 24, 2020
Remdesivir for the Treatment of Covid-19 - Final ReportJohn H Beigel, Kay M Tomashek, Lori E Dodd, et al.
The Lancet. Respiratory Medicine|October 21, 2021
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trialAndre C Kalil, Aneesh K Mehta, Thomas F Patterson, et al.
The Lancet. Respiratory Medicine|May 26, 2022
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trialCameron R Wolfe, Kay M Tomashek, Thomas F Patterson, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Nature Microbiology|January 8, 2026
Gut microbial ethanol metabolism contributes to auto-brewery syndrome in an observational cohortCynthia L Hsu, Shikha Shukla, Linton Freund, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 4, 2023
Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota-Based TherapeuticCharles S Berenson, Bret Lashner, Louis Y Korman, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 10, 2013
Intestinal alkaline phosphatase prevents metabolic syndrome in miceKanakaraju Kaliannan, Sulaiman R Hamarneh, Konstantinos P Economopoulos, et al.
Blood Advances|March 12, 2024
Third-party fecal microbiota transplantation for high-risk treatment-naïve acute GVHD of the lower GI tractZachariah DeFilipp, Ashish V Damania, Haesook T Kim, et al.
Blood Advances|March 30, 2018
Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversityZachariah DeFilipp, Jonathan U Peled, Shuli Li, et al.
The New England Journal of Medicine|May 24, 2020
Remdesivir for the Treatment of Covid-19 - Final ReportJohn H Beigel, Kay M Tomashek, Lori E Dodd, et al.
The Lancet. Respiratory Medicine|October 21, 2021
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trialAndre C Kalil, Aneesh K Mehta, Thomas F Patterson, et al.
The Lancet. Respiratory Medicine|May 26, 2022
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trialCameron R Wolfe, Kay M Tomashek, Thomas F Patterson, et al.
Pageof 3